PITTSBURGH The Food and Drug Administration has approved two new generic versions of a drug for breast cancer.
Teva and Mylan respectively announced Monday and Tuesday the approval of anastrozole tablets in the 1 mg strength. The drug, a treatment for early breast cancer, is a version of AstraZeneca’s Arimidex.
Anastrozole tablets had U.S. sales of $917 million during the 12-month period ended in March, according to IMS Health.
Dr. Reddy’s Labs and Breckenridge Pharmaceutical have also launched versions of Arimidex.